ERBB2 and breast cancer: The therapeutic potential of targeting SOX2-driven CSC supports the clinical use of iadademstat as a novel anti-SOX2 epigenetic breast cancer therapy, particularly in SOX2-enriched luminal-B and HER2-positive subtypes.